Last Updated: November 8, 2026

CITANEST FORTE Drug Patent Profile

Name: CITANEST FORTE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which patents cover Citanest Forte, and what generic alternatives are available?

Citanest Forte is a drug marketed by Astrazeneca and Dentsply Pharm and is included in two NDAs.

The generic ingredient in CITANEST FORTE is epinephrine bitartrate; prilocaine hydrochloride. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the epinephrine bitartrate; prilocaine hydrochloride profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for CITANEST FORTE?
What are the global sales for CITANEST FORTE?
What is Average Wholesale Price for CITANEST FORTE?

Summary for CITANEST FORTE

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	88
Clinical Trials:	2
Patent Applications:	5
What excipients (inactive ingredients) are in CITANEST FORTE?	CITANEST FORTE excipients list
DailyMed Link:	CITANEST FORTE at DailyMed

Drug patent expirations by year for CITANEST FORTE

Recent Clinical Trials for CITANEST FORTE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bozyaka Training and Research Hospital	Phase 4
Diskapi Teaching and Research Hospital	Phase 4

See all CITANEST FORTE clinical trials

US Patents and Regulatory Information for CITANEST FORTE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	CITANEST FORTE	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	014763-008	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Dentsply Pharm	CITANEST FORTE DENTAL	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	021383-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.